Compare HLSQ & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLSQ | CDT |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 972.0K | 1.1M |
| IPO Year | 2018 | 2022 |
| Metric | HLSQ | CDT |
|---|---|---|
| Price | $0.28 | $0.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.0M | ★ 1.4M |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 560.42 | N/A |
| EPS | ★ 3.56 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.07 |
| 52 Week High | $0.77 | $112,500.00 |
| Indicator | HLSQ | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 10.69 | 21.36 |
| Support Level | N/A | $0.07 |
| Resistance Level | $0.45 | $170.00 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | -0.01 | 4.74 |
| Stochastic Oscillator | 8.91 | 8.94 |
Tessera Defense and Homeland Security Inc develops and acquires technologies that identify, track, and counter physical threats across defense, security, critical infrastructure, and first-response markets - building a portfolio around the growing need for earlier, more accurate threat detection as UAVs and other autonomous systems reshape the operating environment. The Company's portfolio includes Zorronet, an AI-powered autonomous command-and-control platform, and DFSL, a developer of LADAR-based counter-UAS and perimeter security systems.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.